Evidence map›Paper›PMID 39149323›Full record

ArticlebioRxiv : the preprint server for biology2024

TFE3 fusions direct an oncogenic transcriptional program that drives OXPHOS and unveils vulnerabilities in translocation renal cell carcinoma.

Jiao Li, Kaimeng Huang, Fiona McBride, Ananthan Sadagopan, Daniel S Gallant, Meha Thakur, Prateek Khanna, Bingchen Li, Maolin Ge, Cary N Weiss and 7 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Jiao LiDepartment of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA, USA.ORCID 0000-0002-8027-5877
Kaimeng HuangDepartment of Medicine, Harvard Medical School; Boston, MA, USA.ORCID 0000-0002-0552-209X
Fiona McBrideDepartment of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA, USA.
Ananthan SadagopanDepartment of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA, USA.
Daniel S GallantDepartment of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA, USA.
Meha ThakurDepartment of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA, USA.
Prateek KhannaDepartment of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA, USA.
Bingchen LiDepartment of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA, USA.
Maolin GeKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Cary N WeissDepartment of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA, USA.
Mingkee AchomDepartment of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA, USA.ORCID 0000-0002-7908-3368
Qingru XuDepartment of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA, USA.
Kun HuangMolecular Imaging Core and Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Birgitta A RybackDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Miao GuiLiangzhu Laboratory, Zhejiang University, Hangzhou 311121, Zhejiang, China; Department of Obstetrics and Gynecology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, Zhejiang, China.
Liron Bar-PeledDepartment of Medicine, Harvard Medical School; Boston, MA, USA.
Srinivas R ViswanathanDepartment of Medical Oncology, Dana-Farber Cancer Institute; Boston, MA, USA.

Funding

Probing the role of somatic X-chromosome alterations in shaping cancer sex differencesR01CA286652 · NCI · DANA-FARBER CANCER INST · PI VISWANATHAN, SRINIVAS RAGHAVAN, ZHANG, CHENG-ZHONG · 2023 to 2025
$2.7M
Molecular mechanisms and therapeutic targeting of activated NRF2 signaling in MiT/TFE translocation renal cell carcinomaR01CA279044 · NCI · DANA-FARBER CANCER INST · PI Srinivas Raghavan Viswanathan · 2023 to 2026
$2.0M
Deciphering the Role of Reductive Stress in Non Small Cell Lung CancerR37CA260062 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Liron Bar-Peled · 2022 to 2026
$1.9M
Targeting the CDK4/6 pathway in MiT/TFE-translocation renal cell carcinomaR21CA296230 · NCI · DANA-FARBER CANCER INST · PI Srinivas Raghavan Viswanathan · 2025 to 2026
$475k
NCI NIH HHS R01 CA279044NCI NIH HHS R01 CA286652NCI NIH HHS R21 CA296230NCI NIH HHS R37 CA260062
6 · The paper itself

Abstract

Translocation renal cell carcinoma (tRCC) is an aggressive subtype of kidney cancer driven by

Identifiers

PMID39149323
PMCPMC11326252

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.